ホーム › 濾胞性リンパ腫 › テネシー › Nashville
Nashville、TNにおける濾胞性リンパ腫の臨床試験
Nashvilleとその周辺地域（約30マイル以内）の拠点で、濾胞性リンパ腫に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
被験者募集中第1/2相
- Tennessee Oncology, Pllc Nashville, Nashville
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
被験者募集中第1相
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
被験者募集中第2/3相
- SCRI Oncology Partners ( Site 7000), Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
被験者募集中第1/2相
- SCRI Oncology Partners ( Site 0100), Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
被験者募集中第1相
- SCRI Oncology Partners, Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
被験者募集中第3相
- Research Site, Nashville
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
被験者募集中第2相
- Research Site, Nashville
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
被験者募集中第3相
- Tennessee Oncology, Nashville
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
被験者募集中第3相
- Vanderbilt University Medical Center, Nashville
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
被験者募集中第1相
- Vanderbilt University/Ingram Cancer Center, Nashville
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
被験者募集中第3相
- Vanderbilt-Ingram Cancer Center, Nashville
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
被験者募集中第1/2相
- Vanderbilt University Medical Center, Nashville
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
被験者募集中第2相
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
被験者募集中第1/2相
- TriStar BMT, Nashville
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
被験者募集中第1相
- Tennessee Oncology, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
被験者募集中第1相
- Tennessee Oncology, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Nashville
他の都市における濾胞性リンパ腫の試験
- New York City, NY24件の研究
- Milwaukee, WI19件の研究
- Houston, TX18件の研究
- Boston, MA17件の研究
- Baldwin Park, CA16件の研究
- Seattle, WA15件の研究
- Durham, NC15件の研究
- Columbus, OH13件の研究
- Salt Lake City, UT13件の研究
- Chicago, IL12件の研究
- San Antonio, TX12件の研究
- Philadelphia, PA12件の研究
Nashvilleにおける他の研究
- 非小細胞肺癌97件の研究
- 乳がん81件の研究
- 転移性癌70件の研究
- 大腸癌69件の研究
- がん（全種類）65件の研究
- 卵巣がん49件の研究
- 前立腺がん43件の研究
- 肺がん40件の研究
- 頭頸部扁平上皮癌39件の研究
- 膵臓がん39件の研究
- 子宮内膜がん38件の研究
- 悪性黒色腫33件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。